Investegate announcements from F. Hoffmann-La Roche Ltd, U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patientsSince the beginning of the pandemic, more than one million people